Who are GSK580299 (CervarixTM)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gardasil 9 rescue dose, Gardasil9, Gardasil 9 Suspension for Injection, GSK580299, GSK Biological's HPV vaccine, Active Comparator: GARDASIL ®9.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gsk580299-cervarixtm.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

GSK580299 (CervarixTM) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GSK580299 (CervarixTM) (GSK580299 (CervarixTM)) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Recombinant HPV vaccine. Area: Oncology / Immunology.

phase 3 Recombinant HPV vaccine Human papillomavirus types 16 and 18 (L1 capsid protein) Oncology / Immunology Biologic Live · refreshed every 30 min

Target snapshot

GSK580299 (CervarixTM) (GSK580299 (CervarixTM)) — GlaxoSmithKline. Cervarix is a bivalent human papillomavirus (HPV) vaccine that stimulates immune responses against HPV types 16 and 18 to prevent cervical cancer and related precancerous lesions.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GSK580299 (CervarixTM) TARGET	GSK580299 (CervarixTM)	GlaxoSmithKline	phase 3	Recombinant HPV vaccine	Human papillomavirus types 16 and 18 (L1 capsid protein)
Gardasil 9 rescue dose	Gardasil 9 rescue dose	Boston Medical Center	marketed	Recombinant HPV vaccine	Human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, 58
Gardasil9	Gardasil9	Boston Medical Center	marketed	Recombinant HPV vaccine	HPV L1 capsid protein (types 6, 11, 16, 18, 31, 33, 45, 52, 58)
Gardasil 9 Suspension for Injection	Gardasil 9 Suspension for Injection	Erasmus Medical Center	marketed	Recombinant HPV vaccine	Human papillomavirus L1 capsid protein (types 6, 11, 16, 18, 31, 33, 45, 52, 58)
GSK580299, GSK Biological's HPV vaccine	GSK580299, GSK Biological's HPV vaccine	GlaxoSmithKline	phase 3	Recombinant HPV vaccine	Human papillomavirus (HPV) virus-like particles
Active Comparator: GARDASIL ®9	Active Comparator: GARDASIL ®9	Shanghai Bovax Biotechnology Co., Ltd.	phase 3	Recombinant HPV vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Recombinant HPV vaccine class)

Boston Medical Center · 2 drugs in this class
GlaxoSmithKline · 2 drugs in this class
Erasmus Medical Center · 1 drug in this class
Shanghai Bovax Biotechnology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK580299 (CervarixTM) — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk580299-cervarixtm. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab